Bio-Techne Corp (TECH) To Go Ex-Dividend on August 24th

Bio-Techne Corp (NASDAQ:TECH) declared a quarterly dividend on Wednesday, August 12th. Investors of record on Monday, August 24th will be given a dividend of 0.65 per share by the biotechnology company on Friday, August 28th. This represents a c) annualized dividend and a yield of 3.6%. The ex-dividend date of this dividend is Monday, August 24th. This is a 712.5% increase from Bio-Techne’s previous quarterly dividend of $0.08.

Bio-Techne has a payout ratio of 15.4% meaning its dividend is sufficiently covered by earnings. Analysts expect Bio-Techne to earn $2.01 per share next year, which means the company should continue to be able to cover its $0.32 annual dividend with an expected future payout ratio of 15.9%.

Bio-Techne Price Performance

TECH opened at $72.17 on Friday. The company has a fifty day moving average price of $66.99 and a two-hundred day moving average price of $59.22. The firm has a market capitalization of $11.30 billion, a PE ratio of 62.76, a P/E/G ratio of 8.60 and a beta of 1.28. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.18 and a current ratio of 4.49. Bio-Techne has a 52 week low of $43.19 and a 52 week high of $72.39.

Bio-Techne (NASDAQ:TECH) last released its earnings results on Wednesday, August 12th. The biotechnology company reported $0.52 earnings per share for the quarter, meeting the consensus estimate of $0.52. The firm had revenue of $321.19 million for the quarter, compared to analyst estimates of $314.63 million. Bio-Techne had a return on equity of 13.37% and a net margin of 14.97%.The company’s quarterly revenue was up 1.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.53 earnings per share. As a group, analysts anticipate that Bio-Techne will post 1.76 earnings per share for the current year.

About Bio-Techne

Bio-Techne Corporation (NASDAQ:TECH) is a global life sciences company that develops, manufactures and sells high-quality reagents, instruments and services for the research, diagnostic and bioprocessing markets. Its core product offerings include recombinant proteins, antibodies, immunoassays, nucleic acid probes and kits, single-cell analysis solutions and automated protein analysis systems. Flagship brands such as R&D Systems, Novus Biologicals, ProteinSimple and Advanced Cell Diagnostics provide researchers and clinicians with reliable tools for cell biology, immunology, proteomics and genomics applications.

Headquartered in Minneapolis, Minnesota, Bio-Techne serves customers across North America, Europe and the Asia-Pacific region through a combination of direct sales, distributors and strategic partnerships.